ReviewMicroorganisms2021
Consolidated Bioprocessing: Synthetic Biology Routes to Fuels and Fine Chemicals.
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Overcoming cellular secretion bottlenecks: advanced secretion engineering and molecular tailoring for next-generation microbial α-amylases with enhanced industrial performance.World journal of microbiology & biotechnology · 2026Review
- Recent advances in biomass deconstruction, microbial conversion, artificial intelligence, and carbon capture for sustainable bioenergy.Bioresources and bioprocessing · 2026Review
- Genomic and secretomic analyses of Blastobotrys yeasts reveal key xylanases for biomass decomposition.Applied microbiology and biotechnology · 2025Article
- Unlocking circular bioeconomy potential of termite-gut yeasts: dual bioremediation and biodiesel production.Frontiers in bioengineering and biotechnology · 2025Review
- Biofuel production from lignocellulose via thermophile-based consolidated bioprocessing.Engineering microbiology · 2024Review
- Biocompatible α-Methylenation of Metabolic Butyraldehyde in Living Bacteria.Angewandte Chemie (International ed. in English) · 2023Article
- High-throughput genetic engineering of nonmodel and undomesticated bacteria via iterative site-specific genome integration.Science advances · 2023Article
- Microbial β-glucanases: production, properties, and engineering.World journal of microbiology & biotechnology · 2023Review
- Editorial: Design and construction of microbial cell factories for the production of fuels and chemicals.Frontiers in bioengineering and biotechnology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The long road from emerging biotechnologies to commercial "green" biosynthetic routes for chemical production relies in part on efficient microbial use of sustainable and renewable waste biomass feedstocks. One solution is to apply the consolidated bioprocessing approach, whereby microorganisms convert lignocellulose waste into advanced fuels and other chemicals. As lignocellulose is a highly complex network of polymers, enzymatic degradation or "saccharification" requires a range of cellulolytic enzymes acting synergistically to release the abundant sugars contained within. Complications arise from the need for extracellular localisation of cellulolytic enzymes, whether they be free or cell-associated. This review highlights the current progress in the consolidated bioprocessing approach, whereby microbial chassis are engineered to grow on lignocellulose as sole carbon sources whilst generating commercially useful chemicals. Future perspectives in the emerging biofoundry approach with bacterial hosts are discussed, where solutions to existing bottlenecks could potentially be overcome though the application of high throughput and iterative Design-Build-Test-Learn methodologies. These rapid automated pathway building infrastructures could be adapted for addressing the challenges of increasing cellulolytic capabilities of microorganisms to commercially viable levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.